Syndax Pharmaceuticals, Inc.
Michael A Metzger (Chief Executive Officer) sells SNDX shares
About this filing
Syndax Pharmaceuticals, Inc. (SNDX) filed Form 4 (insider transaction) with the SEC on Jul 9, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Michael A Metzger · Chief Executive Officer, Director
Rule 10b5-1 plan
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | M · exercise or conversion of a derivative | +32,375 | $6.38 | $206,552.50 | 517,218 | Direct |
| Jul 8, 2026 | S · open-market saleFootnotes F1, F2 | −32,375 | $24.24 | $784,776.48 | 484,843 | Direct |
| Jul 8, 2026 | M · exercise or conversion of a derivativeStock Option (Right to buy)Footnotes F3 | +32,375 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,564,551 options to purchase shares of common stock that are vested and immediately exercisable and a total of 813,949 options to purchase shares of common stock that have not yet vested.
- F2 The sale prices ranged from $24.00 to $24.43
- F3 This option is fully vested.
More SNDX filings
- 4
Filed Oct 30, 2026
- 144
Filed Oct 29, 2026
- SC 13G
Filed Aug 7, 2026
- 10-Q
Filed Aug 4, 2026
- 8-K
Filed Aug 4, 2026
- 8-K
Filed Jul 14, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.